Sit Investment Associates Inc. raised its position in Quest Diagnostics Inc (NYSE:DGX) by 907,772.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 199,732 shares of the medical research company’s stock after acquiring an additional 199,710 shares during the period. Sit Investment Associates Inc.’s holdings in Quest Diagnostics were worth $19,672,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in DGX. WFG Advisors LP lifted its stake in shares of Quest Diagnostics by 45.3% in the 2nd quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock worth $107,000 after acquiring an additional 301 shares during the period. Sun Life Financial INC lifted its stake in shares of Quest Diagnostics by 14,142.9% in the 2nd quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock worth $111,000 after acquiring an additional 990 shares during the period. Acrospire Investment Management LLC lifted its stake in shares of Quest Diagnostics by 300.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock worth $178,000 after acquiring an additional 1,200 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Quest Diagnostics in the 2nd quarter worth $180,000. Finally, Parametrica Management Ltd acquired a new stake in shares of Quest Diagnostics in the 3rd quarter worth $206,000. Institutional investors own 88.84% of the company’s stock.

Quest Diagnostics Inc (NYSE:DGX) opened at $100.37 on Thursday. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78. Quest Diagnostics Inc has a twelve month low of $90.10 and a twelve month high of $112.96. The firm has a market cap of $13,680.00, a PE ratio of 20.91, a price-to-earnings-growth ratio of 2.05 and a beta of 0.60.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The firm had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.92 billion. During the same period last year, the firm posted $1.37 EPS. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. equities research analysts anticipate that Quest Diagnostics Inc will post 5.65 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 9th will be issued a dividend of $0.45 per share. The ex-dividend date is Monday, January 8th. This represents a $1.80 annualized dividend and a yield of 1.79%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.50%.

In other Quest Diagnostics news, EVP J. E. Davis sold 63,880 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total transaction of $6,303,678.40. Following the completion of the transaction, the executive vice president now directly owns 101,423 shares in the company, valued at approximately $10,008,421.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.75% of the company’s stock.

Several analysts have recently commented on DGX shares. Canaccord Genuity restated a “buy” rating and issued a $118.00 target price on shares of Quest Diagnostics in a research note on Wednesday, September 13th. Raymond James Financial reiterated a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, September 25th. ValuEngine cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Credit Suisse Group reduced their price objective on shares of Quest Diagnostics from $110.00 to $99.00 and set a “neutral” rating for the company in a research note on Thursday, September 28th. Finally, Zacks Investment Research cut shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company’s stock. Quest Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $106.20.

TRADEMARK VIOLATION WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/11/sit-investment-associates-inc-acquires-199710-shares-of-quest-diagnostics-inc-dgx.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Stock Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related stocks with our FREE daily email newsletter.